The update breaks a near-term regulatory expectation. Before this filing, the standing plan was to resubmit the RGX-121 BLA in the third quarter of 2026; the company now says it does not expect to resubmit in the near term. That is a meaningful timeline reset, not a routine confirmation of the prior clinical hold situation.
The trigger is five previously treated patients with asymptomatic spine MRI findings. The findings were small nodules or cystic masses detected through expanded monitoring in participants treated roughly three to six years ago, while no brain nodules or masses were found. (Regulatory update) 〔0〕
The company’s reassuring clinical framing does not remove the regulatory problem. All five participants remain clinically stable or improved, and investigators consider the findings nonserious and likely benign, but the filing also acknowledges that their nature and causation are unconfirmed. (Regulatory update) 〔1〕 Because the FDA has imposed a clinical hold and the company is waiting for the full hold letter, the key uncertainty is now whether RGX-121 can support an eventual resubmission at all—and on what additional evidence or timeline.
Net read: materially worse than the market’s prior setup for RGX-121. The Duchenne BLA submission and wet-AMD data remain identified as upcoming catalysts, but those programs do not offset the immediate loss of the MPS II regulatory path. (Regulatory update) 〔2〕
Read the original 8-K on SEC EDGAR ↗